Nefiracetam

Nefiracetam
Clinical data
Routes of
administration		 Oral
ATC code none
Legal status
Legal status
  • Unscheduled (US)
Pharmacokinetic data
Biological half-life 3-5 hours[1]
Identifiers
CAS Number 77191-36-7 N
PubChem (CID) 71157
ChemSpider 64299 YesY
UNII 1JK12GX30N YesY
ChEMBL CHEMBL260829 YesY
ECHA InfoCard 100.163.910
Chemical and physical data
Formula C14H18N2O2
Molar mass 246.305 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Nefiracetam is a nootropic antidementia drug of the racetam family.[2]

Nefiracetam's cytoprotective actions are mediated by enhancement of GABAergic, cholinergic, and monoaminergic neuronal systems. It has been shown to effectively treat apathy and improve motivation in post-stroke patients. It has been shown to exhibit antiamnesia effects for the Alzheimer's type and cerebrovascular type of dementia.[3][4] In addition, it has also been shown to have antiamnesia effects against a wide variety of memory impairing substances, including: ethanol, chlorodiazepoxide (Librium), scopolamine, bicuculline, picrotoxin, and cycloheximide.[5]

Concerns

Studies of long term consumption of nefiracetam in humans and primates have shown it to have no toxicity.[6][7] However, animals which metabolize nefiracetam differently from humans and primates are at risk for renal and testicular[8][9] toxicity. Dogs especially are particularly sensitive, which has been shown to be caused by a specific metabolite, M-18.[10] Higher doses than those in dogs were needed to cause testicular toxicity in rats, although no toxicity was seen in monkeys. Additionally, there has been no evidence of toxicity during clinical trials.[6][7]

See also

References

  1. ↑ Fujimaki Y, Sudo K, Hakusui H, Tachizawa H, Murasaki M (September 1992). "Single- and multiple-dose pharmacokinetics of nefiracetam, a new nootropic agent, in healthy volunteers". The Journal of Pharmacy and Pharmacology. 44 (9): 750–4. doi:10.1111/j.2042-7158.1992.tb05513.x. PMID 1360528.
  2. ↑ Murphy, Keith J; Foley, Andrew G; O'Connell, Alan W; Regan, Ciaran M (29 June 2005). "Chronic Exposure of Rats to Cognition Enhancing Drugs Produces a Neuroplastic Response Identical to that Obtained by Complex Environment Rearing". Neuropsychopharmacology. 31: 90–100. doi:10.1038/sj.npp.1300810. PMID 15988469.
  3. ↑ Robinson RG, Jorge RE, Clarence-Smith K, Starkstein S (2009). "Double-blind treatment of apathy in patients with poststroke depression using nefiracetam". The Journal of Neuropsychiatry and Clinical Neurosciences. 21 (2): 144–51. doi:10.1176/appi.neuropsych.21.2.144. PMID 19622685.
  4. ↑ Robinson RG, Jorge RE, Clarence-Smith K (2008). "Double-blind randomized treatment of poststroke depression using nefiracetam". The Journal of Neuropsychiatry and Clinical Neurosciences. 20 (2): 178–84. doi:10.1176/appi.neuropsych.20.2.178. PMID 18451188.
  5. ↑ Hiramatsu M, Shiotani T, Kameyama T, Nabeshima T (Feb 1997). "Effects of nefiracetam on amnesia animal models with neuronal dysfunctions". Behavioural Brain Research. 83 (1-2): 107–115. doi:10.1016/s0166-4328(97)86053-6.
  6. 1 2 M Murasaki; M Inami; J Ishigooka; H Watanabe; M Utsumi; T Matsumoto; et al. (1994). "Phase I study on DM-9384 (nefiracetam)". Jpn. Pharmacol. Ther. 22: 3539–3587.
  7. 1 2 E Otomo; K Kogure; S Hirai; F Goto; K Hasegawa; Y Tazaki; et al. (1994). "Clinical evaluation of DM-9384 in the treatment of cerebrovascular disorders: early phase II study". Jpn. Pharmacol. Ther. (22): 3589–3624.
  8. ↑ Shimada, M; Shikanai, Y; Shimomura, K; Harada, S; Watanabe, G; Taya, K; Kato, M; Furuhama, K (2003). "Investigation of testicular toxicity of nefiracetam, a neurotransmission enhancer, in rats". Toxicology letters. 143 (3): 307–15. doi:10.1016/s0378-4274(03)00197-8. PMID 12849691.
  9. ↑ Shimomura, K; Shimada, M; Hagiwara, M; Harada, S; Kato, M; Furuhama, K (2004). "Testicular toxicity induced in dogs by nefiracetam, a neutrotransmission enhancer". Reproductive toxicology (Elmsford, N.Y.). 18 (3): 423–30. doi:10.1016/j.reprotox.2004.01.008. PMID 15082078.
  10. ↑ Goto, Koichi; Ishii, Yoshikazu; Jindo, Toshimasa; Furuhama, Kazuhisa (3 March 2003). "Effect of Nefiracetam, a Neurotransmission Enhancer, on Primary Uroepithelial Cells of the Canine Urinary Bladder". Toxicological Sciences. 1 (72): 164–70. doi:10.1093/toxsci/kfg010. PMID 12604846.
This article is issued from Wikipedia - version of the 6/11/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.